Expert Interview
Comparing results metastatic melanoma in PD-1 progressing patients. IOVA, IDRA, ONCS, REPL, CMPI all have results at this year's SITC in this 2L PD-1 refractory melanoma population. We ask an expert to compare trial designs and results
Ticker(s): IOVA, IDRA, ONCS, REPL, CMPIHem-Oncologist treating PD-1 refractory patients, up to date on the literature of the differnet approaches (TIL therapy, TLR9, plasmid IL-12 elecrtroporation, oncolytic viruses) and having attended and reviewed recent results from SITC from different companies. Knowledge of regulatory critera for approval important. A recent PI a study in this indication potentially a plus.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
